Replimune Group, Inc. (NASDAQ:REPL) Stake Boosted by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. increased its stake in Replimune Group, Inc. (NASDAQ:REPL) by 300.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,238,883 shares of the company’s stock after purchasing an additional 1,679,553 shares during the period. Goldman Sachs Group Inc. owned 3.65% of Replimune Group worth $18,874,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Tower Research Capital LLC TRC lifted its stake in Replimune Group by 236.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,207 shares of the company’s stock valued at $35,000 after buying an additional 2,958 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Replimune Group by 352.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,833 shares of the company’s stock valued at $58,000 after purchasing an additional 5,324 shares during the period. Exchange Traded Concepts LLC grew its position in Replimune Group by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 7,837 shares of the company’s stock worth $66,000 after purchasing an additional 1,988 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of Replimune Group in the fourth quarter valued at approximately $76,000. Finally, Handelsbanken Fonder AB bought a new stake in shares of Replimune Group during the fourth quarter valued at approximately $101,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Insider Buying and Selling at Replimune Group

In other news, COO Colin Love sold 17,615 shares of Replimune Group stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total value of $113,969.05. Following the transaction, the chief operating officer now owns 777,345 shares of the company’s stock, valued at approximately $5,029,422.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, COO Colin Love sold 17,615 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $6.47, for a total transaction of $113,969.05. Following the completion of the sale, the chief operating officer now directly owns 777,345 shares of the company’s stock, valued at approximately $5,029,422.15. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Konstantinos Xynos sold 15,881 shares of Replimune Group stock in a transaction on Friday, June 7th. The stock was sold at an average price of $7.50, for a total value of $119,107.50. Following the completion of the transaction, the insider now owns 117,131 shares in the company, valued at $878,482.50. The disclosure for this sale can be found here. In the last three months, insiders sold 107,598 shares of company stock valued at $712,516. 20.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

REPL has been the topic of several analyst reports. HC Wainwright raised their target price on Replimune Group from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Wedbush restated an “outperform” rating and set a $16.00 price objective on shares of Replimune Group in a research note on Thursday, June 6th. Finally, Barclays increased their target price on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday, June 7th.

Replimune Group Stock Performance

REPL opened at $8.71 on Thursday. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $24.28. The company has a market capitalization of $534.92 million, a price-to-earnings ratio of -2.69 and a beta of 1.15. The business has a 50 day moving average price of $6.81 and a two-hundred day moving average price of $7.59. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.72 and a quick ratio of 10.72.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, May 16th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.04. Research analysts predict that Replimune Group, Inc. will post -3.31 EPS for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.